Clinical Trial Update: Development of a New Family of HIV Latency Regulators (LRAs) Targeting the Tat Viral Protein

View source ↗

Summary

A clinical trial update reports development of a new family of latency-reversing agents targeting the HIV Tat protein, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Snippet

Sponsor: University Hospital, Montpellier | Conditions: HIV Infections | Status: RECRUITING